Atelerix
The company develops hypothermic gel technology using a natural seaweed-derived biopolymer to stabilize and transport biological samples at room temperature. Its product range, including CytoStor and LeukoStor, enables the shipment of cells, tissues, organoids, and blood without the need for cryopreservation or dry ice. These solutions target life science researchers, drug development laboratories, and cell therapy manufacturers seeking to maintain sample viability while simplifying logistics.
Visit websiteNewcastle upon Tyne, UK
Biotechnology
Life Sciences
Healthtech
Logistics
Funding summary
- Total raised
- €894K
- Funding rounds
- 1
Investors in Atelerix
Investors on record for Atelerix. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Atelerix?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors